All articles by GlobalData Healthcare

UK point-of-care production of cell therapies could arrive in 2025

The UK government is proposing to allow groundbreaking manufacturing methods that would permit cell therapies to be made at the…
Europe’s TCR immunotherapy licensing deals surge 123% above US in 2024

Licensing agreement deal values for innovator T-cell receptor (TCR) immunotherapy drugs for European biopharmaceutical companies increased by 325% (by $921…
AHA 2024: Phase III BROOKLYN trial – safety and efficacy of obicetrapib in HeFH patients

On 18 November, at the American Heart Association (AHA) 2024 Annual Scientific Sessions in Chicago, Illinois, US, during a late-breaking…
AHA 2024: CV effectiveness of GLP-1RA + Empagliflozin therapy in adults with T2D

At the American Heart Association’s (AHA) 2024 Annual Scientific Sessions, which took place from 16 November to 18 November in…
AHA 2024: Tirzepatide improves outcomes for major heart failure with HFpEF and obesity in SUMMIT

On November 16, at the 100th American Heart Association (AHA) Scientific Sessions 2024 in Chicago, Illinois, US, results were presented…

AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults

On November 16, during the American Heart Association (AHA) 2024 Annual Scientific Sessions in Chicago, IL, US, findings from the…
AHA 2024: lerodalcibep shows promising results in open-label extension trial in HeFH patients

On November 16, at the American Heart Association (AHA) 2024 Annual Scientific Sessions in Chicago, IL, US, clinical trial results…
IDWeek 2024: strategic approaches and challenges in mpox vaccination

At IDWeek 2024 in Los Angeles, California, recent updates on mpox (formerly known as monkeypox) were discussed. Significant advancements and…
Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor optimism improved…
Roche to leverage Dyno Therapeutics tech for novel gene therapies in neuro disorders

On October 24, Dyno Therapeutics announced the formation of a new strategic partnership with Roche to develop adeno-associated virus (AAV)…